Entrada Therapeutics, Inc. TRDA
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a rare genetic drug developer. Its lead program, ENTR-601-44, is in Phase 2 for Duchenne muscular dystrophy (exon 44 skipping). Its next catalyst on record is ENTR-601-44: Cohort 2 topline (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ENTR-601-44 — Cohort 2 topline (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ENTR-601-44 | DMD exon 44 (ELEVATE-44-201 Phase 1/2) | oligonucleotide-other | Phase 2 |
| ENTR-601-45 | DMD exon 45 (Phase 1/2) | oligonucleotide-other | Phase 1 |
| ENTR-601-50 | DMD exon 50 | oligonucleotide-other | Phase 1 |
| ENTR-601-51 | DMD exon 51 | oligonucleotide-other | Pre-clinical |
| ENTR-801 | Ocular | oligonucleotide-other | Pre-clinical |
Recent results and decisions
- Oct 14, 2026positive Cohort 1 (5 mg/kg): favorable safety; mean dystrophin +0.10% (n=6, nominal p=0.03) vs -0.02% placebo; no functional benefit expected or observed.
A mean increase of 0.10% (n = 6, nominal p = 0.03) from baseline in dystrophin production was observed in study participants who received ENTR-601-45 versus a 0.02% mean decrease from baseline in study participants who received placebo
Filing - Oct 14, 2026completed enrollment Cohort 2 (10 mg/kg) enrollment complete and dosing ongoing.
Cohort 2 enrollment is complete and dosing at 10 mg/kg is ongoing.
Filing - Oct 14, 2026met Cohort 1 of ELEVATE-45-201 Phase 1/2 study of ENTR-601-45 met primary safety and tolerability objectives at 5 mg/kg, with a 0.10% mean increase in dystrophin production.
Topline results met the primary objectives of favorable safety and tolerability. The secondary objectives also met Company expectations and demonstrated a 0.10% mean increase in dystrophin and a 0.15% mean increase in exon skipping compared with baseline levels in treated participants.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.